Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program

Benitec Biopharma Inc. announced the enrollment of the first oculopharyngeal muscular dystrophy (OPMD) patient into the OPMD natural history phase of the BB-301 clinical development program.
[Benitech Biopharma, Inc.]
Press Release
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News